Used to prevent nausea and vomiting caused by moderate and/or high-vomiting chemotherapy for 3-5 consecutive days
Conditions
Interventions
experimental group:granisetron transdermal patch
Sponsors
Harbin Institute of Hematology and Oncology
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1) Aged 18 years and above, gender is not limited; 2) Malignant tumors confirmed by histopathology or cytology; 3) ECOG score was 0-2, and the survival was expected to be more than 3 months. 4) Initial or retreatment chemotherapy, this time received 2 consecutive days or more of chemotherapy; 5) Targeted patients treated with combination and/or single drug; 6) Voluntary participation and informed consent signed by the patient; 7) Ability to read, understand and independently complete patient diaries.
Exclusion criteria
Exclusion criteria: 1) Taboos (e.g. patients with gastrointestinal obstruction) or allergies to serotonin, which belong to 5-hydroxytryptamine receptor antagonists; 2) Whole body or local radiotherapy is required during the observation period; 3) Liver and kidney diseases, infections, serious neurological or psychiatric diseases, combined with vestibular dysfunction, gastroparesis, cancer pain, and other diseases that may potentially cause and/or aggravate nausea and vomiting; 4) Those who are taking drugs to treat symptoms of brain tumors or epilepsy; 5) Pregnancy, breastfeeding or intentional pregnancy; 6) There are patients who are judged by other researchers to be unsuitable for enrollment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The proportion of patients with nausea and vomiting reaching complete response (CR) from the beginning of chemotherapy to 24 hours after the end of chemotherapy (PEEP); | — |
Countries
China
Contacts
Public ContactMa Jun
Harbin Institute of Hematology and Oncology
Outcome results
None listed